Fluorescence-based assay for hexanal detection using polydiacetylenes
Radetec Diagnostics presents a fluorescence-based assay utilizing polydiacetylenes (PDAs) for efficient hexanal detection. This low-cost, high-throughput method offers promising detection capabilities with potential applications in quality control and food safety.
Overview
Radetec Diagnostics has developed an innovative fluorescence-based assay for detecting hexanal using polydiacetylenes (PDAs). This assay promises to revolutionize the detection of hexanal, a marker of lipid oxidation and spoilage, by providing a low-cost, high-throughput solution. With the ability to process numerous samples simultaneously, this technology is ideal for industries involved in quality control and food safety, particularly those dealing with dry samples.
Technical specifications
The assay operates by leveraging the unique properties of PDAs, which undergo spectral shifts upon interacting with specific molecules like hexanal. Key features include:
- Low-cost operation: Each sample requires less than $0.01 worth of PDA material.
- High-throughput capability: The assay can be executed in 384-well plates, allowing for the analysis of dozens of samples per run.
- Advanced selectivity and sensitivity: Computational modeling and AI-driven fluorescence pattern analysis are employed to enhance the selectivity and sensitivity of PDAs for hexanal detection. The current detection limit is being optimized to reach 1 ppm.
Technology readiness level
The technology is currently at TRL 3, indicating experimental proof of concept. Future steps involve computational modeling, synthesis of optimized PDA compositions, experimental validation, and method optimization to meet specific detection thresholds for hexanal.
About Radetec Diagnostics
Radetec Diagnostics is a Melbourne-based bio-nanotechnology company that specializes in the production and application of highly fluorescent quantum dot nanoparticles. These nanoparticles are engineered to be stable in buffers and can be conjugated with various biologically active molecules, such as antibodies. Beyond nanoparticle synthesis, the company develops specialized laboratory equipment for lateral flow assay development, including automated stripers for protein application on nitrocellulose and electronic readers for fluorescence and colorimetric quantification. By combining this proprietary nanotechnology with molecular and serological assays, Radetec creates highly sensitive, cost-effective point-of-care diagnostic tools.
These innovations are primarily directed toward revolutionizing the detection of infectious diseases, including sexually transmitted infections and animal health conditions. The company’s diagnostic platform aims to improve accessibility to rapid, private testing, helping to mitigate the societal stigma and high costs associated with traditional lab-based molecular testing. Through research partnerships and custom synthesis services, Radetec also supports the broader scientific community in developing tailored nanomaterials and lateral flow applications for various biomedical and industrial research needs.
Inquire about this partnering listing
Industry applications
delivered to your inbox.